Relmada Therapeutics, Inc.RLMD
Price (close)
$3.81
Market cap
$406.4M
P/E
—
Revenue (TTM)
—
Net income
-$61.9M
Dividend yield
—
1-year total return
129.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What Relmada Therapeutics, Inc. does.
corporation), is a publicly traded, clinical-stage biotechnology company. We substantially redesigned our development programs following
a comprehensive strategic review in late 2024 and early 2025. We concluded in our review that the most promising path to create shareholder
value was to lever our extensive drug development expertise and clinical operations capabilities by acquiring new development candidates,
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$59.5M | -$125.8M | -$157.0M | -$98.8M | -$80.0M | -$57.4M |
| Free cash flow | -$209.9M | — | — | — | — | — |
More on RLMD.
- Relmada Therapeutics, Inc. summary
- Relmada Therapeutics, Inc. financial statements
- Relmada Therapeutics, Inc. key metrics
- Relmada Therapeutics, Inc. health scores and style box
- Relmada Therapeutics, Inc. earnings
- Relmada Therapeutics, Inc. dividends
- Relmada Therapeutics, Inc. valuation
- Relmada Therapeutics, Inc. ownership and insiders
- Relmada Therapeutics, Inc. peers
Figures from Relmada Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.